Matt Kronmiller - Profile and Investment Details

Investor Profile

Matt Kronmiller is a Venture Capital based in San Francisco, California, United States with a diverse investment portfolio that includes companies such as Dermira, Phenomix, NuPathe, Cydan, TRIA Beauty, SynGen, Vivaldi Biosciences, PTC Therapeutics, Sunesis Pharmaceuticals, Epizyme, Hyperion Therapeutics, Avera Pharmaceutical, Oculis, Altheos, Ascendancy, VIA Pharmaceuticals, Xeris Pharmaceuticals, BrainCells, Imara, Aragon Surgical, Oculex Pharmaceuticals, Reliant Pharmaceuticals, CymaBay Therapeutics, NextWave Pharmaceuticals, Nevro, NextCure, IDEV Technologies, Accriva Diagnostics, Interleukin Genetics, Epocrates, Aviir, Pharmion, Aciex Therapeutics, Nabsys, Ion Torrent, Civitas Therapeutics, Fabric Genomics (formerly Omicia), Xilio Therapeutics, Vtesse, Radiant Medical, EnteroMedics, Cadence Pharmaceuticals, Conatus Pharmaceuticals, Gossamer Bio, Calypso Medical, VYNE Therapeutics, KBP Biosciences, Merus, Presidio Pharmaceuticals, Gritstone Oncology, NBI Development, PharmAkea Therapeutics, Twist Bioscience, Kezar Life Sciences, Iterum Therapeutics, MAP Pharmaceuticals. Over time, Matt Kronmiller has demonstrated experience in supporting a range of businesses across various sectors.

While it is not publicly confirmed whether Matt Kronmiller is currently seeking new investment opportunities, their past investments provide valuable insight into the types of projects and industries that have attracted their attention.

Startups and entrepreneurs operating in sectors related to Health Care, Genetics, Women Founded, Medical Testing, Investment Management, Women Led, Life Science, Biotech, Healthcare, Biotechnology, Genomics, Health Diagnostics, Therapeutics, Media and Entertainment, Pharmaceuticals, Biopharma may find it worthwhile to explore potential connections with Matt Kronmiller, as their portfolio suggests a familiarity and interest in this area.

Understanding Matt Kronmiller’s investment history can offer useful context for founders considering outreach and help identify whether there is a potential fit based on strategic alignment and market focus.